News
AVXL
3.680
-2.65%
-0.100
Weekly Report: what happened at AVXL last week (0415-0419)?
Weekly Report · 1d ago
Class Action Lawsuit against Anavex Life Sciences (NASDAQ:AVXL)
TipRanks · 5d ago
Weekly Report: what happened at AVXL last week (0408-0412)?
Weekly Report · 04/15 09:09
Anavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL
Barchart · 04/15 04:45
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Anavex Life Sciences Corp. Will present at the Noble Capital Markets Virtual Healthcare Equity Conference on April 18th, 2024. Anavex is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders.
Barchart · 04/11 06:30
Weekly Report: what happened at AVXL last week (0401-0405)?
Weekly Report · 04/08 09:10
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Anavex Life Sciences's (NASDAQ:AVXL) cash burn rate is up 10% in the last year. The company is burning through cash to fund its growth. Its cash runway is 4.9 years from December 2023. Anavex life Sciences doesn't record any revenue over the past year. It's an early stage company and may need to raise more cash to grow its business.
Simply Wall St · 04/01 10:38
Weekly Report: what happened at AVXL last week (0325-0329)?
Weekly Report · 04/01 09:10
AVXL STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights and Remedies Against Anavex Life Sciences Corporation
Robbins LLP reminds investors that a shareholder filed a class action on behalf of Anavex Life Sciences Corporation (NASDAQ: AVXL) An avex shareholder alleges the company misled investors about the likelihood of success of its clinical trial. You may be eligible to participate in the class action against anavex life sciences corporation.
Barchart · 03/31 00:46
Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL
Barchart · 03/26 04:45
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corp. (AVXL) Investors
The Law Offices of Frank R. Cruz announces a class action lawsuit has been filed on behalf of Anavex Life Sciences Corp. Investors. The lawsuit was filed on January 2, 2024. AnaveX investors have until May 13, 2024 to file a lead plaintiff motion.
Barchart · 03/25 11:09
Weekly Report: what happened at AVXL last week (0318-0322)?
Weekly Report · 03/25 09:10
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Anavex Life Sciences Corp. Will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024. Anavex is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders.
Barchart · 03/25 06:30
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corp. (AVXL) Investors
A class action lawsuit has been filed on behalf of investors who purchased Anavex Life Sciences Corp. Securities between February 1, 2022 and January 1, 2024. Investors have until May 13, 2024 to file a lead plaintiff motion against the company. On January 2, 2024, AnaveX announced results from a clinical study in Pediatric Rett Syndrome. The Company blamed deficiencies in the study on a placebo effect.
Barchart · 03/21 17:01
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corp. (AVXL) Investors
Law Offices of Howard G. Smith announces a class action lawsuit has been filed on behalf of investors who purchased Anavex Life Sciences Corp. Securities between February 1, 2022 and January 1, 2024. AnaveX investors have until May 13, 2024 to file a lead plaintiff motion. On January 2, 2024, anavex announced results from a study that blamed deficiencies in the study on a placebo effect.
Barchart · 03/21 11:43
AVXL INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that investors have until May 13, 2024 to seek appointment as lead plaintiff of the Anavex class action lawsuit. AnaveX Life Sciences Corporation (NASDAQ: AVXL) stock purchasers or acquirers have until February 1, 2022 to apply to be a lead plaintiff in the lawsuit. If you suffered substantial losses and wish to serve as the lead plaintiff, please contact Robbins Geller. The Firm is one of the world's leading class action firms.
Barchart · 03/19 06:50
Anavex Life Sciences Corporation Stockholder Alert: Robbins LLP Reminds Investors of AVXL Class Action
Robbins LLP reminds investors that a shareholder filed a class action on behalf of Anavex Life Sciences Corporation (NASDAQ: AVXL) An avex shareholder alleges the company misled investors about the likelihood of success of its clinical trial. You may be eligible to participate in the class action against anavex life sciences corporation.
Barchart · 03/18 15:31
Weekly Report: what happened at AVXL last week (0311-0315)?
Weekly Report · 03/18 09:10
AVLX, SGH and ETNB are among pre market losers
On the Move AVLX, SGH and ETNB are among pre market losers. 89bio and iHeartMedia are among the pre market gainers. CERo Therapeutics Holdings and Castle Biosciences are among those that lost in the biotech sector.
Seeking Alpha · 03/15 20:48
AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
A class action lawsuit has been filed against Anavex Life Sciences Corp. Investors are encouraged to join this case. Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm. The lawsuit seeks to recover damages for investors in the class action.
Barchart · 03/14 13:22
More
Webull provides a variety of real-time AVXL stock news. You can receive the latest news about Anavex Life Scie through multiple platforms. This information may help you make smarter investment decisions.
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.